Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of in vivo labelled dendritic cell migration in cancer patients.
Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, Fiorentini G. Ridolfi R, et al. Among authors: riccobon a. J Transl Med. 2004 Jul 30;2(1):27. doi: 10.1186/1479-5876-2-27. J Transl Med. 2004. PMID: 15285807 Free PMC article.
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R. Ridolfi L, et al. Among authors: riccobon a. J Transl Med. 2013 May 31;11:135. doi: 10.1186/1479-5876-11-135. J Transl Med. 2013. PMID: 23725550 Free PMC article.
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M. de Rosa F, et al. Among authors: riccobon a. J Transl Med. 2014 Jul 22;12:209. doi: 10.1186/1479-5876-12-209. J Transl Med. 2014. PMID: 25053129 Free PMC article. Clinical Trial.
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis.
Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Scarpi E, Guidoboni M, Migliori G, Sanna S, Tauceri F, Verdecchia GM, Riccobon A, Valmorri L, Ridolfi R. Ridolfi L, et al. Among authors: riccobon a. Clin Dev Immunol. 2010;2010:504979. doi: 10.1155/2010/504979. Epub 2010 Sep 27. Clin Dev Immunol. 2010. PMID: 20936106 Free PMC article. Clinical Trial.
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Framarini M, Tauceri F, Migliori G, Brolli C, Gentili G, Petracci E, Nanni O, Riccobon A, Ridolfi R, Guidoboni M. de Rosa F, et al. Among authors: riccobon a. Melanoma Res. 2017 Aug;27(4):351-357. doi: 10.1097/CMR.0000000000000356. Melanoma Res. 2017. PMID: 28654547
Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M. Ridolfi L, et al. Among authors: riccobon a. BMJ Open. 2018 Aug 5;8(8):e021701. doi: 10.1136/bmjopen-2018-021701. BMJ Open. 2018. PMID: 30082356 Free PMC article.
38 results